Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer
PurposeWe investigated the correlation of 18F-AlF-NOTAPRGD2 (18F-RGD) uptake during positron emission tomography (PET) with tumoral programmed death-ligand 1 (PD-L1) expression and explored its potential in immune checkpoint inhibitor treatment.MethodsForty-two mice were subcutaneously injected with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.913631/full |
| _version_ | 1811326365837819904 |
|---|---|
| author | Leilei Wu Leilei Wu Jingru Liu Jingru Liu Jingru Liu Shasha Wang Menglin Bai Menglin Bai Menglin Bai Min Wu Min Wu Min Wu Zhenhua Gao Jianing Li Jinming Yu Jinming Yu Jinming Yu Jie Liu Jie Liu Xue Meng Xue Meng |
| author_facet | Leilei Wu Leilei Wu Jingru Liu Jingru Liu Jingru Liu Shasha Wang Menglin Bai Menglin Bai Menglin Bai Min Wu Min Wu Min Wu Zhenhua Gao Jianing Li Jinming Yu Jinming Yu Jinming Yu Jie Liu Jie Liu Xue Meng Xue Meng |
| author_sort | Leilei Wu |
| collection | DOAJ |
| description | PurposeWe investigated the correlation of 18F-AlF-NOTAPRGD2 (18F-RGD) uptake during positron emission tomography (PET) with tumoral programmed death-ligand 1 (PD-L1) expression and explored its potential in immune checkpoint inhibitor treatment.MethodsForty-two mice were subcutaneously injected with CMT-167 lung carcinoma cells. A total of 30 mice with good growth tumor and good general condition were selected. 18F-RGD PET scanning was performed on days 0, 2, 4, 6, 9, and 11 with five mice per day. Immunohistochemistry (IHC) for PD-L1 was performed on each specimen obtained from tumors. Thirty patients with advanced non-small cell lung cancer (NSCLC) were scanned using 18F-RGD PET/CT, and Milliplex multifactor detection analyzed serum PD-1/PD-L1 expression of twenty-eight of them. Thirteen of them were analyzed immunohistochemically using core needle biopsy samples obtained from primary tumors.ResultsThirty mice were scanned by 18F-RGD PET/CT and analyzed for PD-L1 expression in tumor cells by IHC finally. Maximum standard uptake value (SUVmax) and mean SUV (SUVmean) were significantly lower in relatively-higher-PD-L1-expression tumors than in relatively-low-PD-L1-expression tumors (P < 0.05). In patients, the SUVmax was significantly negatively correlated with tumoral PD-L1 expression by IHC (P=0.014). SUVmean, peak SUV (SUVpeak), and gross tumor volume (GTV) were also negatively correlated with PD-L1, but without significance (P > 0.05). SUVmax, SUVmean, SUVpeak, and GTV were negatively correlated with serum PD-1 and PD-L1, but not significantly. According to the receiver operating characteristic curve analysis, significant correlations between SUVmax and tumoral PD-L1 expression in both mice and patients were present (P < 0.05).ConclusionHigher 18F-RGD uptake is correlated with depressed PD-L1 expression in tumor cells, and SUVmax is the best parameter to display tumoral expression of PD-L1. 18F-RGD PET may be useful for reflecting the immune status of NSCLC. |
| first_indexed | 2024-04-13T14:49:19Z |
| format | Article |
| id | doaj.art-f7d90da1bc154fbdbc7b8bd4376a462d |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-13T14:49:19Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-f7d90da1bc154fbdbc7b8bd4376a462d2022-12-22T02:42:40ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-06-011310.3389/fendo.2022.913631913631Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung CancerLeilei Wu0Leilei Wu1Jingru Liu2Jingru Liu3Jingru Liu4Shasha Wang5Menglin Bai6Menglin Bai7Menglin Bai8Min Wu9Min Wu10Min Wu11Zhenhua Gao12Jianing Li13Jinming Yu14Jinming Yu15Jinming Yu16Jie Liu17Jie Liu18Xue Meng19Xue Meng20Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong University Cancer Center, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaResearch Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaPurposeWe investigated the correlation of 18F-AlF-NOTAPRGD2 (18F-RGD) uptake during positron emission tomography (PET) with tumoral programmed death-ligand 1 (PD-L1) expression and explored its potential in immune checkpoint inhibitor treatment.MethodsForty-two mice were subcutaneously injected with CMT-167 lung carcinoma cells. A total of 30 mice with good growth tumor and good general condition were selected. 18F-RGD PET scanning was performed on days 0, 2, 4, 6, 9, and 11 with five mice per day. Immunohistochemistry (IHC) for PD-L1 was performed on each specimen obtained from tumors. Thirty patients with advanced non-small cell lung cancer (NSCLC) were scanned using 18F-RGD PET/CT, and Milliplex multifactor detection analyzed serum PD-1/PD-L1 expression of twenty-eight of them. Thirteen of them were analyzed immunohistochemically using core needle biopsy samples obtained from primary tumors.ResultsThirty mice were scanned by 18F-RGD PET/CT and analyzed for PD-L1 expression in tumor cells by IHC finally. Maximum standard uptake value (SUVmax) and mean SUV (SUVmean) were significantly lower in relatively-higher-PD-L1-expression tumors than in relatively-low-PD-L1-expression tumors (P < 0.05). In patients, the SUVmax was significantly negatively correlated with tumoral PD-L1 expression by IHC (P=0.014). SUVmean, peak SUV (SUVpeak), and gross tumor volume (GTV) were also negatively correlated with PD-L1, but without significance (P > 0.05). SUVmax, SUVmean, SUVpeak, and GTV were negatively correlated with serum PD-1 and PD-L1, but not significantly. According to the receiver operating characteristic curve analysis, significant correlations between SUVmax and tumoral PD-L1 expression in both mice and patients were present (P < 0.05).ConclusionHigher 18F-RGD uptake is correlated with depressed PD-L1 expression in tumor cells, and SUVmax is the best parameter to display tumoral expression of PD-L1. 18F-RGD PET may be useful for reflecting the immune status of NSCLC.https://www.frontiersin.org/articles/10.3389/fendo.2022.913631/full18 F-RGD PETnegative correlationtumoral PD-L1 expressionSUVmaxnon-small cell lung cancer |
| spellingShingle | Leilei Wu Leilei Wu Jingru Liu Jingru Liu Jingru Liu Shasha Wang Menglin Bai Menglin Bai Menglin Bai Min Wu Min Wu Min Wu Zhenhua Gao Jianing Li Jinming Yu Jinming Yu Jinming Yu Jie Liu Jie Liu Xue Meng Xue Meng Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer Frontiers in Endocrinology 18 F-RGD PET negative correlation tumoral PD-L1 expression SUVmax non-small cell lung cancer |
| title | Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer |
| title_full | Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer |
| title_fullStr | Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer |
| title_full_unstemmed | Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer |
| title_short | Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer |
| title_sort | negative correlation between 18f rgd uptake via pet and tumoral pd l1 expression in non small cell lung cancer |
| topic | 18 F-RGD PET negative correlation tumoral PD-L1 expression SUVmax non-small cell lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.913631/full |
| work_keys_str_mv | AT leileiwu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT leileiwu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jingruliu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jingruliu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jingruliu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT shashawang negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT menglinbai negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT menglinbai negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT menglinbai negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT minwu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT minwu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT minwu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT zhenhuagao negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jianingli negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jinmingyu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jinmingyu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jinmingyu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jieliu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT jieliu negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT xuemeng negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer AT xuemeng negativecorrelationbetween18frgduptakeviapetandtumoralpdl1expressioninnonsmallcelllungcancer |